Resumen de Investigación

Analyzed using Evidence Intelligence™

Tirzepatide improves glycemic control and weight loss sustainability in type 2 diabetes

Última actualización 4 de julio de 2026

Key finding

For tirzepatide-treated participants achieving HbA1c ≤48 mmol/mol (6.5%) at 52 weeks, 75–84% sustained this until study end.

This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Risk of bias

High Risk

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.

Clinical relevance

These findings are significant for clinicians treating type 2 diabetes, as maintaining glycemic control and weight loss is crucial for reducing long-term complications. The sustained effects of tirzepatide may offer a valuable treatment option for patients struggling with diabetes management.

Keep in mind

Unclear effectiveness for some outcomes due to lack of detailed data. Results may not be generalizable beyond the study population. Limited information on long-term safety and efficacy.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Ewan RP, Stefano DP, Imre P, et al. Sustainability of Glycemic Control and Weight Loss with Tirzepatide in Type 2 Diabetes: A Post Hoc Analysis of the SURPASS-4 Trial. Diabetes. 2025;74(10):1850-1862. doi:10.2337/db25-0276

View DOI View on PubMed View on PMC

Efectos Principales

75–84% of tirzepatide-treated participants maintained HbA1c ≤48 mmol/mol (6.5%) until study end, with a decrease of -2.5 mmol/mol (p=0.001).

79–82% of participants who lost ≥10% of their weight at 52 weeks maintained this loss, with an average reduction of -5 kg (p=0.002).

Diabetes management self-efficacy scores improved significantly by 0.8 points (p=0.03).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and 1,5-Anhydroglucitol, Body weight, Diabetes management self-efficacy, and 2 more.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

1,5-Anhydroglucitol

Evidence topic

HbA1c Reduction

Primary intervention

Tirzepatide

Primary outcomes

1,5-Anhydroglucitol
Body weight
Diabetes management self-efficacy

Evidence topics

HbA1c Reduction Weight Loss GLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

1,5-Anhydroglucitol Body weight Diabetes management self-efficacy

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 5 evidence relationships
Includes primary outcome data
Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

GLP-1 Receptor Agonists and Body Weight

Evidencia relacionada

Relación de evidencia

GLP-1 Receptor Agonists and HbA1c

Guardar evidencia

Relación de evidencia

GLP-1 Receptor Agonists and Fasting Glucose

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

1,5-Anhydroglucitol

Tirzepatide → 1,5-Anhydroglucitol

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Body weight

Tirzepatide → Body weight

Evidence Intelligence™

EvidenceScore™: 84; Strong
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 8 studies

Add to Evidence Tracker

Diabetes management self-efficacy

Tirzepatide → Diabetes management self-efficacy

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 100; Very Positive
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

Gestational diabetes mellitus incidence

Tirzepatide → Gestational diabetes mellitus incidence

Evidence Intelligence™

EvidenceScore™: Emerging; Score 59 · Based on 1 study
ImpactScore™: 50; Neutral
ConsistencyScore™: unclear; Not enough independent studies

Based on 1 study

Add to Evidence Tracker

HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™

EvidenceScore™: 85; Strong
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 9 studies

Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

La Evidencia Sugiere

Tirzepatide led to a significant decrease in HbA1c levels by -2.5 mmol/mol.
Participants experienced an average weight loss of -5 kg, maintained by 79–82%.
Self-efficacy in diabetes management improved by 0.8 score.

A quién se aplica

Adults diagnosed with type 2 diabetes.
Patients seeking effective weight management solutions.

Tener en Cuenta

The study's findings are based on a specific trial population.
Results may not apply to all demographics or diabetes types.
Further research is needed to confirm long-term effects and safety.

Entre Líneas

Unclear effectiveness for some outcomes due to lack of detailed data.
Results may not be generalizable beyond the study population.
Limited information on long-term safety and efficacy.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Medications

Detailed evidence

GLP-1 Receptor Agonists → HbA1c

Medications

Evidence Intelligence™

EvidenceScore™: 85; Strong
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 9 studies

View evidence

Medications

Detailed evidence

GLP-1 Receptor Agonists → Body Weight

Medications

Evidence Intelligence™

EvidenceScore™: 84; Strong
ImpactScore™: 100; Very Positive
ConsistencyScore™: 100; consistent

Based on 8 studies

View evidence

Incluido en estas colecciones de evidencia

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

9 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

9 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

8 studies

outcome_hub

Measures Body Weight as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Explora más en Evidence Explorer

Jump to pre-filtered views in Evidence Explorer.

All studies on Tirzepatide and HbA1c

Intervention: TirzepatideOutcome: HbA1c

9 results

All studies on Tirzepatide and Body weight

Intervention: TirzepatideOutcome: Body weight

8 results

All studies on Tirzepatide

Intervention: Tirzepatide

9 results

All studies measuring HbA1c

Outcome: HbA1c

9 results

All studies measuring Body weight

Outcome: Body weight

8 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 84.4 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 84.6 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 27 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve fasting glucose?

Strong Evidence

GLP-1 Receptor Agonists may improve Fasting Glucose.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
1,5-Anhydroglucitol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve diabetes incidence and prevention?

Moderate Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Diabetes Incidence and Prevention.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Gestational diabetes mellitus incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

HbA1c Reduction Evidence Hub Weight Loss Evidence Hub GLP-1 Receptor Agonists Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Tirzepatide and HbA1c All studies on Tirzepatide and Body weight All studies on Tirzepatide and 1,5-Anhydroglucitol All studies on Tirzepatide and Diabetes management self-efficacy

Related research

Read related research summaries.

Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes Tirzepatide improves glycemic control in early-onset type 2 diabetes Tirzepatide improves cardiometabolic health in obesity.Tirzepatide enhances insulin sensitivity in type 2 diabetes Switching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristics

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.